Anticoagulation in cirrhosis: a new paradigm?

Area of Science:

• Hepatology
• Hematology
• Thrombosis and Hemostasis

Background:

• The liver is central to the coagulation cascade, and liver disease significantly impacts hemostasis.
• Cirrhosis leads to impaired synthesis of coagulation factors and altered platelet counts due to portal hypertension.
• Traditional views considered cirrhosis patients at high bleeding risk, leading to routine transfusions.

Purpose of the Study:

• To explore the complex hemostatic alterations in liver cirrhosis.
• To re-evaluate bleeding and thrombotic risks in cirrhosis patients.
• To assess the adequacy of standard coagulation tests and the role of anticoagulation.

Main Methods:

• Review of recent evidence on hemostasis in liver cirrhosis.
• Analysis of bleeding and thrombotic event associations.
• Evaluation of standard laboratory coagulation tests versus comprehensive assessments.

Main Results:

• Cirrhosis involves complex hemostatic changes beyond simple factor deficiency.
• Stable cirrhosis may have rebalanced hemostasis, but decompensation can shift it towards bleeding or thrombosis.
• Increased risk of venous thromboembolism (e.g., portal vein thrombosis) is noted; bleeding risk correlates with portal hypertension severity.
• Anticoagulant therapy is safe and beneficial, reducing thrombosis and improving survival.
• Standard coagulation tests are insufficient for assessing hemostatic status and predicting bleeding.

Conclusions:

• Liver cirrhosis presents a complex hemostatic profile, not fully captured by standard tests.
• Bleeding risk in cirrhosis is more linked to portal hypertension than hemostatic imbalance.
• Anticoagulation is safe and effective for managing thrombotic risks in cirrhosis.
• Comprehensive hemostatic assessments are needed for guiding clinical management.